Señales en vivo de LIAN | Maximiza tus Ganancias con Getagraph.com

VENDER 107455 min ago

@ $4.83

Emitido: 14 feb 2024 @ 09:35

Retorno: -93.39%

Live Chart Being Loaded With Signals

Commentary (4 abr 2024 @ 16:00):

Stats
Volumen de hoy	2.48M
Volumen promedio	959 835
Capitalización de mercado	34.47M
EPS	$0 ( 2024-03-25 )
Próxima fecha de ganancias	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.390
ATR14	$0.00600 (1.80%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Gu Ehong	Sell	1 731	Ordinary Shares
2024-04-09	Gu Ehong	Sell	17 889	Ordinary Shares
2024-02-15	Poukalov Konstantin	Buy	36 300	Ordinary Shares
2024-02-15	Poukalov Konstantin	Sell	19 218	Ordinary Shares
2024-02-15	Poukalov Konstantin	Sell	36 300	Stock Option (Right to Buy)

INSIDER POWER
70.87
Last 79 transactions
Buy: 50 859 501 \| Sell: 7 434 951

Volumen Correlación

Largo: 0.35 (neutral)

Corto: 0.36 (neutral)

Signal:(47.977) Neutral

LianBio Correlación

10 Correlaciones Más Positivas
IPHA	0.872
PRDS	0.853
ORIC	0.841
AMRB	0.836
CHRS	0.811
BGNE	0.801

10 Correlaciones Más Negativas
EMBC	-0.83

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

LianBio Correlación - Moneda/Commodity

0.78
( moderate )

0.74
( moderate )

0.00
( neutral )

-0.61
( weak negative )

LianBio Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$-1.00M (0.00 %)
EPS:	$-1.020

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-1.00M (0.00 %)
EPS:	$-1.020

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.03

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.450

Financial Reports:

No articles found.

LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.